From BDAZ post

Because most BET inhibitors do not distinguish between the different BET proteins and inhibit all of them indiscriminately, our study urges caution with the clinical use, prophylactic or therapeutic, of pan-BET inhibitors in people at risk or afflicted with COVID-19."

From Cell article

Together, this demonstrates that BD2-selective BETi drugs are lead candidates for rapid clinical translation to prevent COVID-19 injury in the heart.

 BD2-selective drugs, such as ABBV-744 and apabetalone, have limited side effects. Apabetalone has been used for up to 3 years in >1,700 humans at risk of cardiac disease, with efficacy in preventing heart failure and a favorable safety profile (Nicholls et al., 2021; 

It would seem the BD2 selectivity of APB makes it an exception the the findings in BDAZ article.

Somebody prove me wrong.